STATE COUNCIL

ON DRUG POLICIES



Release:



The President of the State Council policies on Drogas CONED-SP,
in response to the resolution adopted at the 90th Meeting
Ordinary 10.29.2015, publishes, in accordance with Art. 9 of Resolution
SJDC-055, of 06.26.2013, the following Statements:


Statement coned-SP No. 01 of 10.29.2015
The use of hallucinogenic substances or onirophrenics for
treatment of problematic use of psychoactive substances should be
considered an option that requires scientific research.


Statement coned-SP No. 02 of 10.29.2015
Scientific research with the use of hallucinogenic substances or
onirophrenics including the development of options
treatment for problematic substance use, should
be encouraged financially by development institutions in order to
ensure the realization of quantitative research, qualitative and
randomized controlled clinical trials.


Statement coned-SP No. 03 of 10.29.2015
The semisynthetic or synthetic compounds based on
active principles of Tabernanthe iboga and other species of the genus
Tabernaemontana (Apocynaceae family) must have their potential
therapeutic in the treatment of problematic substance use
psychoactive investigated through scientific research.


Statement coned-SP No. 04 of 10.29.2015
The derivatives of the active principles and other Tabernanthe iboga
Tabernaemontana species of the genus (Apocynaceae family)
particularly ibogaine formulations can only be
administered for the treatment of the abuse of substances
psychoactive in a hospital environment, with supervision and control
doctors, given the practice of the profession and good recommendations
clinical practice, including rigorous clinical and
psychiatric and psychological assessment and monitoring
psychotherapeutic